Clinical Trial

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Study acronym: Velarite-LTE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.
Protocol Amendment History 3 changes
notable Trial sites expanded: 24 -> 28 locations 2026-08-07
notable Trial sites expanded: 16 -> 24 locations 2026-07-08
notable Trial sites expanded: 7 -> 14 locations 2026-05-12
Trial Details
NCT Number NCT07223697
Lead Sponsor Hoffmann-La Roche
Conditions Atopic Dermatitis
Enrollment 120 participants
Start Date 2026-01-08
Primary Completion 2033-03-01 (estimated)
Study Completion 2033-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-06